IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing–remitting MS mononuclear cells: Gene expression analysis employing all reported protein–protein interactions

The molecular mechanism by which interferon beta (IFN-beta) is effective in treating multiple sclerosis is not well understood. Mononuclear cells from therapy-naïve MS patients, IFN-beta-1b-treated MS patients, and healthy controls were analyzed to examine mRNA changes that characterize both the disease and its treatment. The scientific literature was comprehensively searched for all protein-protein interactions. In MS patients who had never been treated with IFN-beta, statistical analysis revealed coordinate changes in mRNA expression for proteins reported in the literature as "regulated by IFN-beta." As a positive control for this approach, samples from a separate MS patient cohort showed significant change of these same genes during in vivo treatment with IFN-beta-1b.The strength of effect observed for regulation by IFN-beta was greater than for IFN-alpha, IFN-gamma (Th1), or IL-4 (Th2). Of the sets we investigated, the most strongly affected by disease was the subset defined by regulation by both IFN-beta and IFN-alpha. Changes in cells from therapy-naïve MS patients thus anticipated the importance of IFN-beta in therapy. These findings are a significant step towards marrying MS disease etiology and IFN-beta mechanism of action at a molecular level.

[1]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[2]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[3]  Murali Ramanathan,et al.  Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.

[4]  R. Fisher.  Statistical methods for research workers , 1927, Protoplasma.

[5]  R. Harris,et al.  Tissue Typing Using a Routine One‐Step Lymphocyte Separation Procedure , 1970, British journal of haematology.

[6]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[7]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[8]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[9]  P. Febbo,et al.  Application of a priori established gene sets to discover biologically important differential expression in microarray data , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[11]  Silke Schmidt,et al.  Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.

[12]  H. Harbo,et al.  Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis , 2007, Nature Genetics.

[13]  Sergei Maslov,et al.  Automatic Pathway Building in Biological Association Networks , 2006 .

[14]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[15]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[16]  Terence P. Speed,et al.  A benchmark for Affymetrix GeneChip expression measures , 2004, Bioinform..

[17]  Ryszard Maleszka,et al.  Microarray reality checks in the context of a complex disease , 2004, Nature Biotechnology.